LEXINGTON, Mass., April 7 /PRNewswire-FirstCall/ -- MacroChem Corporation has announced that Robert J. DeLuccia, its president and chief executive officer, will present an update on the Company’s technologies, products and business strategy on April 11, 2006 at 3:00 pm at the Massachusetts Pavilion at the Annual International Convention of the Biotechnology Industry Organization (BIO 2006) to be held in Chicago. The Company will join approximately thirty other Massachusetts companies and organizations at the Massachusetts Pavilion program.
In his presentation, Mr. DeLuccia will give an update on the business strategy of MacroChem, a specialty pharmaceutical company developing innovative products by capitalizing on its proprietary transdermal drug delivery technologies. He will also discuss the status of the company’s two clinical development stage SEPA-enhanced products: EcoNail(TM), an econazole nail lacquer for treating onychomycosis (fungal nail infections) and Opterone(R), a topical testosterone cream for treating male hypogonadism.
BIO 2006 will draw 18,000 life science professionals from around the world to network and learn about the future of the industry through an expansive exhibit hall and a series of thought-provoking, educational programs. Sponsored by the Biotechnology Industry Organization (BIO), the 14th annual international convention will take place April 9-12 at Chicago’s McCormick Place Convention Center.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail(TM), to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com
Investor/Media Contact: Bernard Patriacca - VP/CFO
(781) 862-4003
MacroChem Corporation
CONTACT: Bernard Patriacca, VP/CFO of MacroChem Corporation, +1-781-862-4003
Web site: http://www.macrochem.com/
